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Expression of GCRG213p, LINE-1
endonuclease variant, significantly different
in gastric complete and incomplete
intestinal metaplasia
Xiaojian Duan1†, Hongwei Lian1†, Jie Li2, Benyan Wu1, Weihua Wang1, Tao Wu1, Changzheng Wang1, Yan Dou3,
Zhongren Zhou4, Bingzhi Wang5, Liyan Xue5* and Gangshi Wang1*

Abstract
Background: Intestinal metaplasia (IM) of the gastric mucosa is classified as complete (Type I) and incomplete IM
(Type II and III) subtypes, which showed significantly different risk for developing to gastric adenocarcinoma (GAC).
GCRG213, a variant of L1-endonuclease (L1-EN), first identified in our lab, was upregulated in GAC tissue. However,
the relationship between GCRG213 and IM subtypes is not clear. Our study explored the association of GCRG213
protein (GCRG213p) with IM subtypes.
Methods: Gastric cancer and/or para-tumor tissue samples were collected from 123 patients who underwent
gastrectomy for intestinal type gastric adenocarcinoma. The subtypes of IM were characterized with Alcian
blue-periodic acid-Schiff and High Iron Diamine-Alcian blue staining methods. Immunohistochemistry of
GCRG213p was performed, and its expression in gastric adenocarcinoma and para-tumor tissue including
dysplasia, IM, and normal mucosa were analyzed.
Results: GCRG213p was expressed in 48.94% IM, 57.14% dysplasia and 55.32% GAC, respectively. GCRG213p
expression was higher in well and moderately differentiated adenocarcinoma (P = 0.037). In IM glands,
GCRG213p expressed mainly in the cytoplasm of absorptive enterocytes with defined brush borders, but not
in goblet cells. The expression of GCRG213p in type I IM (90.00%) was significantly higher than that in type II
(36.36%) and type III (25.00%) (P < 0.001). In normal gastric mucosa, GCRG213p was exclusively positive in the
cytoplasm of gastric chief cells.
Conclusions: The expression of GCRG213p in complete IM was significantly higher than in incomplete IM,
which implies that GCRG213p may play a role on the developing of IM to adenocarcinoma. GCRG213p was
exclusively expressed in chief cells, suggesting that it might be involved in cell differentiation from the chief
cells to IM.
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Background
Gastric cancer is the second highest cause of cancerrelated death in the world [1]. The accepted model for the
development of the intestinal type of non-cardia gastric
cancer, known as Correa’s cascade, consists stepwise progression from chronic active gastritis, multifocal atrophic
gastritis, intestinal metaplasia (IM), dysplasia and finally
gastric adenocarcinoma (GAC) [2]. IM in the gastric mucosa is a precancerous lesion of GAC and the “Point of no
return” [3], which remains the focus of GAC surveillance
and prevention [4, 5]. According to the evidence in a nationwide cohort study in Netherlands, the annual incidence of gastric cancer was 0.25% for patients with IM
within 5 years after diagnosis [6]. IM also takes a long time
to develop to GAC. A recent nationwide observational cohort study in Sweden where the incidence of GAC is relatively low, revealed that approximately 1 in 39 subjects
with IM will develop to GAC within 20 years after IM
diagnosis [7]. Since the incidence of IM progress to gastric
cancer is low, it is not efficient to surveil IM patients for
GAC. Currently, the clinical management of the patients
with IM still remains of challenging task.
IM has long been recognized as heterogeneous, which
is classified into three subtypes based on mucin stain, including type I (complete IM) with only sialomucin, type
II with mixed sialomucin (incomplete IM) and sulfomucin and type III with only sulfomucin (incomplete IM)
[8]. Accumulated experiences with human specimens
showed the simultaneous expression of different types of
mucins in the same metaplastic epithelial cells, suggesting that the metaplastic process represents a gradual
phenotypic change [8, 9]. It is unclear whether these
three types of IM follow a chronologic sequence. Incomplete IM was considered to be associated with higher
gastric cancer risk compared with complete IM. A multicenter study revealed that the incidence rate of GAC
was 2.76 and 5.76 per 1000 person-years for complete
IM and incomplete IM patients, respectively [10]. In
general, patients with IM type III more frequently developed to GAC [11]. Therefore, biomarkers to triage high
risk IM patients for GAC will help the surveillance of
gastric cancer.
Gastric Cancer Related Gene 213 (GCRG213) was first
identified in our lab and was upregulated in human GAC
tissue at mRNA level [12]. GCRG213 sequence shared
90% similarity with human long interspersed nucleotide
elements (LINE-1, L1) and could be a variant of L1endonuclease (L1-EN). L1 constitutes a large family of retrotransposable elements, accounting for 17% of the human genome [13]. L1-EN is a part of L1-ORF2p [14, 15].
Our previous study proposed that GCRG213 could be a
spliced L1-ORF2 and a variant of L1-EN, since GCRG213
protein (GCRG213p) shares high sequence alignments
with L1-EN and possesses conserved residues which are
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crucial for L1-EN phosphate binding, metal binding and
catalytic activity [16]. Overexpression of GCRG213p was
reported in both primary GAC and lymph node metastasis
[16]. Our preliminary data also showed GCRG213p expression in gastric precancerous lesions, including dysplasia and IM. However, the distribution of GCRG213p
expression in the gastric complete and incomplete IM is
unclear. In current study, we further investigate the
GCRG213p expression in the stepwise system from normal gastric mucosa, IM, dysplasia and adenocarcinoma by
immunohistochemistry (IHC). In addition, we compared
GCRG213p expression in different subtypes of IM.

Methods
Patients

Gastric specimens from patients who underwent gastrectomy for GAC between 2010 and 2013 were retrieved from the Chinese PLA General Hospital, Beijing,
China. Paraffin-embedded tumor and paired surrounding gastric mucosa tissues were obtained. Samples of intestinal type adenocarcinoma according to Lauren’s
classification, such as papillary and tubular adenocarcinoma, were included, and those with components of diffuse type were excluded. A total of 123 intestinal type
GAC cases were collected. Among them, 47 cases had
both tumor and para-tumor samples, and 76 cases only
had para-tumor IM samples. Besides, three specimens of
normal gastric mucosa resected in operation such as
Whipple procedure were collected.
Immunohistochemistry and assessment

Immunohistochemistry for GCRG213p was performed on
4 μm paraffin sections according to procedure described
previously [17]. Briefly, after antigen retrieval, monoclonal
mouse anti-human GCRG213p antibody, which was produced in our laboratory [18], was added at a dilution of 1:
800 and incubated for 2 h at room temperature. The slides
were then incubated for 1 h in secondary antibody. An
EnVision kit (Dako, Carpinteria, CA, USA) was used to
visualize antibody binding, and slides were subsequently
counterstained with hematoxylin. A PBS-only staining sample was used as a background control. Positive controls for
GCRG213p were represented by sections taken from gastric
cancer. Specific immunostaining for GCRG213p was exclusively confined to the cytoplasm. The staining was scored
independently and in a blinded manner by two investigators.
The inter-observer disagreements were reviewed, followed
by a conclusive judgment by both observers. Immunostaining for GCRG213p was scored by staining intensity and the
percentage of positively stained cells as described formerly,
0 (absent), 1 (weak), 2 (moderate), and 3 (strong) and 0 (0%
positive), 1 (1–30%), 2 (31–60%), and 3(> 60%). The score of
intensity and extension was combined and the minimum
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summed score was 0, and the maximum was 6. An overall
score ≥ 3 was deemed a positive GCRG213p expression.
Histochemical types and classification of IM

Histochemical types of IM was characterized with Alcian
blue-periodic acid-Schiff (AB-PAS) and High Iron
Diamine-Alcian blue (HID-AB) staining methods. The
protocols for AB-PAS and HID-AB staining reported previously were used [19]. All solutions were prepared freshly.
Briefly, for AB-PAS staining, after deparaffinization, the
paraffin slides were stained with AB staining solution (pH
2.5) for 10 min, washed with distilled water, oxidated with
1.0% periodic acid solution for 10 min, stained with Schiff
solution for 10 min and finally washed with distilled water.
For HID-AB staining, the paraffin slides were deparaffinized, reacted with high iron diamine solution (pH 1.5–
1.6) at room temperature for 24 h, washed with distilled
water, stained with AB solution for 10 min, washed with
distilled water, stained with 0.5% neutral red solution for
1–2 min and finally washed with distilled water. Based on
the morphology and histochemistry findings, IM was classified as three types: type I (complete IM), type II and type
III (incomplete IM) [8].
Statistical analysis

Statistical analyses were performed using SPSS 19.0 (SPSS
Inc., Chicago, IL). The differences of GCRG213p expression in GAC, adjacent dysplasia and IM, and the distributions in IM subtypes and in different differentiated degrees
of GAC were compared by using Kruskal-Wallis test or
Mann -Whitney test and a 2-sided P value of 0.05 was
used as the criterion for statistical significance.

Results
GCRG213p expression pattern in gastric IM subtypes

Specimens from 76 cases who only had para-tumor IM
samples were used to perform GCRG213p immunohistochemistry, and histochemical staining (Fig. 1).
GCRG213p expressed mainly in the cytoplasm of absorptive enterocytes with defined brush borders, but the
signal was weak in the enterocytes without brush borders. In the goblet cells, the immunoreactivity was absent. The percentage of GCRG213p in IM type I, type II
and type III were 90, 26 and 35%, respectively (Table 1).
The expression of GCRG213p among the three IM subtypes differed significantly ((P < 0.001), with type I
(complete IM) higher than that in type II or type III (incomplete IM) (Table 1). There is no difference between
the type II and type III subgroups.
GCRG213p expression pattern in human normal gastric
mucosa

GCRG213p was also identified in normal gastric mucosa
samples with yellow-brown signal at the bottom of gastric
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glands where the gastric chief cells located. Other cells in
the gastric mucosa, such as parietal cells, surface foveolar
cells and pylori glands in gastric antrum were negative
(Fig. 2).

GCRG213p expression in gastric IM, dysplasia and gastric
adenocarcinoma

Tissues from 47 patients who had both tumor and paratumor samples were studied with GCRG213p immunohistochemistry. Specific yellow-brown immunostaining
for GCRG213p were found in cytoplasm of the positive
cells (Fig. 3). GCRG213p was extensively expressed in
IM, dysplasia and GAC at 48.9, 57.1 and 55.3%, respectively (Table 2). There was no significantly difference of
GCRG213p expression among IM, dysplasia and GAC
(P = 0.956), but a significant difference of GCRG213p expression between well-to-moderately-differentiated and
poorly-differentiated GAC was noticed (P = 0.036).

Discussion
It is now clear that 2 types of mucous cell metaplasia
develop in the atrophic human stomach and represent
putative preneoplastic lesions: goblet cell IM and spasmolytic polypeptide–expressing metaplasia (SPEM, also
known as pseudopyloric metaplasia) [20, 21] . IM is defined as the replacement of glandular and/or foveolar
epithelia by intestinal epithelia and SPEM as the transdifferentiation of chief cells with TFF2 expression in
gastric mucosa [22]. The true identity of original cells
in gastric IM remains to be established, but two
competing models are advocated [23]. Some studies
propose that the cell of origin for IM resides in the gastric isthmus [24]. However, other researchers have observed some cells that expressed both TFF2, a SPEM
marker, and MUC2, a goblet marker. In the fundus of
Helicobacter pylori-infected Mongolian gerbils, goblet
cells in SPEM glands were observed in the later stages
of infection [21, 25]. Therefore, IM may arise from
SPEM [26] or perhaps directly from chief cells [27]. Indeed, Troy+ chief cells are reported to produce all epithelial lineages present in the corpus in vivo [28]. One
recent study even showed that SPEM can arise by direct reprogramming of existing chief cells, without contribution from gastric stem cells [29], which implies
there exists genetic continuum between differentiated
chief cells and IM. In this study, we found that
GCRG213p positive presented exclusively in chief cells
and in a high percentage of IM glands. Thus, it is
meaningful to speculate that GCRG213p may be related
with the cell differentiation from the chief cell to IM.
The mechanism of GCRG213p on the IM from the
chief cells is worth to be further studied.
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Fig. 1 GCRG213p expression and special acid stains in gastric intestinal metaplasia subtypes. Specific yellow-brown staining was identified in
cytoplasm of the well-differentiated absorptive cells that have a brush-like border in IM cells. a, b, c with GCRG213p, a: type I; b: type II; c: type III;
d, e, f with AB-PAS stains, d: type I; e: type II; f: type III; g, h, i with HID-AB stains, g: type I; h: type II; i: type III

Intestinal metaplasia in the stomach can progress to
low-grade dysplasia and high-grade dysplasia and culminate in GAC [30]. Because of the large surface area
of gastric mucosa and the lack of targeted sampling
Table 1 Expression of GCRG213p in gastric IM subtypes
Subtypes of IM

N

Cases of overall scorea
0–2

P value

4–5

6

Complete IM

I

20

2

6

9

3

90.00

P < 0.001c

Incomplete IM

II

44

28

8

6

2

36.36

P < 0.001d

III

12

9

1

2

0

25.00

P = 0.001e

76

39

15

17

5

48.68

Total
a

3

PRb
(%)

Overall score calculated as (intensity score) plus (percent cells positive score)
as described in methods
PR: Positive rate of GCRG213p expression
c
Among type I, II and III
d
Between type I and III
e
Between type I and II
b

strategy, the true frequency of IM progression to
adenocarcinoma in the stomach is difficult to discern.
The relative risks of GAC were reported from 4- to 11fold higher for the presence of incomplete type in comparison to complete type [31]. A significant association
has been documented between incomplete IM and extensive/multifocal IM [32]. Extensive gastric IM has
been recommended as a high-risk marker for gastric
cancer, according to international recommendations
and guidelines [33, 34]. Therefore, apart from a routine
combination of morphology (Haemotoxylin and Eosin,
H&E staining) and mucins staining (AB-PAS and HIDAB), GCRG213p, whose expression was significantly
different between complete and incomplete IM, might
provide a good merit on evaluating sub-type of IM.
After analyzing gene expression and molecular processes involved in IM subtypes, the incomplete IM
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Fig. 2 GCRG213p expression in human normal gastric mucosa. Serial sections from the same block of normal gastric fundic mucosa were stained
by immunohistochemistry with GCRG213p antibody (the upper row) and H&E (the lower row). a and c: GCRG213p expression in normal gastric
chief cells (a: 100×; c: 400x, IHC); e: GCRG213p was negative in surface faveolar cells (400x). b, d and f: matched gastric mucosa with H&E stain (b:
100x; d: 400x; f: 400x)

Fig. 3 GCRG213p expression in IM, gastric dysplasia and adenocarcinoma. a-c, h & e staining images in gastric IM (a), dysplasia (b) and
adenocarcinoma (c). d-f, representative images of GCRG213p immunostaining in tissue samples from gastric IM (d), dysplasia (e) and
adenocarcinoma (f). (Original magnification 200×, and 400× in block frame)
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Table 2 GCRG213p expression in intestinal metaplasia (IM), dysplasia and gastric adenocarcinoma
Lesions

N

Cases of overall scorea
0–2

3

4–5

6

PRb
(%)

IM

47

24

7

6

10

48.94

Dysplasia

7

3

1

2

1

57.14

Gastric adenocarcinoma

47

21

11

10

5

55.32

Well-to-moderately-differentiated

14

3

3

4

4

78.57

Poorly-differentiated

33

18

6

4

5

45.45

P value

P = 0.956c
P = 0.036d

a

Overall score calculated as (intensity score) plus (percent cells positive score) as described in methods
b
PR: Positive rate of GCRG213p expression
c
Among gastric IM, dysplasia and adenocarcinoma
d
Between well-to-moderately-differentiated and poorly-differentiated adenocarcinoma

shows a higher number of up-regulated differentially
expressed genes and molecular processes than complete
IM, which is in agreement with its higher risk of progression to GC [35]. In fact, complete IM is merely a
weak risk factor for gastric cancer, and it may even
suppress cancer development [10, 36]. Our study
showed that the expression of GCRG213p in IM type I
(complete IM) was significantly higher than in IM type
II and type III (incomplete IM), which implied that
GCRG213p may play a role to decrease the possibility
of developing from IM to dysplasia or adenocarcinoma.
L1-EN is believed to produce the nicking of genomic
deoxyribonucleic acid (DNA). Thus, even simply upregulation of L1-EN could promote the formation of
additional double strand breaks of DNA, which resulted
in cell cycle arrest, apoptosis or senescence. A correlation between L1 expression/retrotransposition and induction of apoptosis was observed in breast cancer
cells, which implies that DNA nicks created by L1 expression and retrotransposition are sensed as a DNA
damaging event, which leads to apoptosis [37]. Therefore, GCRG213p, a L1-EN variant, may have a similar
function to induce cell cycle arrest, apoptosis or senescence in IM, which could explain the complete IM has
a low risk for developing to GAC.

Conclusions
The expression of GCRG213p in complete IM is significantly higher than in incomplete IM, which implies that
GCRG213 may play a protective role on the developing
from IM to adenocarcinoma. This differential expression
pattern also reminds a possible role of GCRG213p as a
biomarker of IM sub-typing. GCRG213p is exclusively
expressed in chief cells, which suggests that GCRG213p
may be associated with the cell differentiation from the
chief cells to IM.
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